LNTH — Lantheus Holdings, Inc. Stock Price, Chart & AI Report

Neutral Feb 26, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Lantheus Holdings reported Q4 2025 revenue of $406.8 million and full-year revenue of $1.54 billion, with adjusted EPS of $1.67 and $6.08 respectively. The company announced a strategic refocus on PET radiodiagnostics and plans to pursue value-maximizing alternatives for radiotherapeutic assets. Despite PYLARIFY sales declining 9.7% in Q4, the company expects up to four FDA approvals in 2026 and provided FY2026 guidance of $1.4-1.45 billion in revenue and $5.00-5.25 adjusted EPS.

LNTH radiopharmaceuticals PET imaging PYLARIFY FDA approvals strategic refocus earnings pipeline advancement

Sentiment note

Mixed results with modest revenue growth (4.0% Q4, 0.5% FY) but declining PYLARIFY sales (-9.7% Q4, -6.5% FY) offset by strategic acquisitions and pipeline expansion. Positive forward guidance and multiple FDA approvals expected in 2026, but the divestiture of legacy SPECT business and shift in strategy suggest operational restructuring. Adjusted EPS growth of 4.7% in Q4 is modest, and full-year adjusted EPS declined from $6.76 to $6.08.

Positive Feb 20, 2026 • 15:55 UTC GlobeNewswire Inc. • Researchandmarkets.Com

PSMA-Targeted Therapy & Radiodiagnostics Competitor Analysis Report 2026: PYLARIFY Exceeds US$ 1 Billion in Net Sales and Became the First Ever Blockbuster Radiodiagnostic

PYLARIFY has become the first blockbuster radiodiagnostic, exceeding $1 billion in 2024 net sales with 24.3% growth. PLUVICTO, a radioligand therapeutic agent, posted $1.392 billion in 2024 sales with 42% growth. PSMA-targeted therapies and radiodiagnostics represent a clinically validated and commercially successful approach for prostate cancer treatment and diagnosis, with multiple radioligands in development.

LNTH NVS PSMA-targeted therapy radiodiagnostics prostate cancer PYLARIFY PLUVICTO radioligand therapy

Sentiment note

PYLARIFY achieved historic milestone as first blockbuster radiodiagnostic with $1.058 billion in 2024 sales and strong 24.3% year-over-year growth, demonstrating robust commercial success and market validation.

Neutral Feb 12, 2026 • 13:00 UTC GlobeNewswire Inc. • Na

Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time

Lantheus Holdings announced it will host an earnings conference call and webcast on February 26, 2026, at 8:00 a.m. ET to discuss its fourth quarter and full year 2025 financial and operating results. The company also recently closed the sale of its SPECT business to SHINE Technologies.

LNTH earnings call fourth quarter 2025 radiopharmaceutical SPECT business sale investor relations

Sentiment note

The article is primarily an announcement of an earnings call and webcast with no forward-looking statements or performance indicators. While the SPECT business sale closure is mentioned, it lacks detail on financial impact or strategic implications, making this a routine corporate announcement without clear positive or negative implications.

Positive Jan 2, 2026 • 13:00 UTC GlobeNewswire Inc. • Na

Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies

Lantheus Holdings has completed the sale of its SPECT diagnostic business to SHINE Technologies, a subsidiary of Illuminated Holdings. The transaction includes diagnostic agents like TechneLite, NEUROLITE, and Cardiolite, along with manufacturing facilities in Massachusetts and Canadian operations. Following the divestiture, Lantheus will focus on its PET radiodiagnostics and microbubbles portfolio.

LNTH SPECT business divestiture radiopharmaceutical diagnostic agents TechneLite Cardiolite NEUROLITE business restructuring

Sentiment note

The company successfully completed a strategic divestiture of its SPECT business, allowing it to focus on higher-growth areas like PET radiodiagnostics and microbubbles. This represents a strategic repositioning toward more innovative product lines and demonstrates execution on planned business transformation.

Negative Dec 23, 2025 • 23:25 UTC The Motley Fool • Jonathan Ponciano

Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year

Nitorum Capital fully exited its stake in Lantheus Holdings, selling 344,444 shares worth $28.2 million in Q3. The exit comes as Lantheus faces significant headwinds including a 77% year-over-year earnings decline, declining sales of its flagship prostate cancer imaging agent, CEO retirement, and margin compression despite strong revenue generation.

LNTH MLM CHDN MNKD Lantheus Holdings earnings decline portfolio exit radiopharmaceuticals

Sentiment note

GAAP EPS fell 77% year-over-year to $0.41, flagship product sales declined 7.4%, stock down 27% over the past year, facing CEO retirement and portfolio restructuring, rising costs from acquisitions and R&D, and execution risks despite strong cash generation.

Negative Nov 13, 2025 • 22:40 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Quantum, Unicycive, Fly-E, and Lantheus on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential securities misconduct for four companies, alleging false statements, misleading financial reporting, and concealment of material facts that impacted stock prices.

QMCO UNCY FLYE LNTH securities investigation class action financial misconduct stock price

Sentiment note

Accused of concealing adverse facts about product competitive positioning and pricing dynamics

Negative Nov 9, 2025 • 13:50 UTC GlobeNewswire Inc. • Faruqi & Faruqi, Llp

LNTH SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Lantheus Investors Have Opportunity to Lead Class Action Lawsuit

Faruqi & Faruqi is investigating potential claims against Lantheus Holdings regarding misleading statements about Pylarify's competitive position, with stock price dropping 28.8% after disappointing Q1 and fiscal year results.

LNTH securities litigation class action shareholder lawsuit stock decline

Sentiment note

Stock price declined 28.8% after reporting below-market Q1 results, reduced growth expectations for Pylarify, and acknowledging competitive challenges impacting pricing dynamics

Negative Nov 8, 2025 • 15:37 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

LANTHEUS CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds Lantheus Stockholders to Contact the Firm Before November 10th Regarding Their Rights

A class action lawsuit has been filed against Lantheus Holdings for allegedly making false and misleading statements about Pylarify's competitive position and pricing dynamics between November 2024 and August 2025.

LNTH class action securities lawsuit Pylarify pricing

Sentiment note

The lawsuit alleges the company concealed material adverse facts about Pylarify's competitive position, misrepresented pricing dynamics, and made misleading statements about business operations and growth potential

Negative Nov 6, 2025 • 19:50 UTC GlobeNewswire Inc. • Rosen Law Firm

LANTHEUS DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Lantheus Holdings, Inc. Investors to Secure Counsel Before Important November 10 Deadline in Securities Class Action – LNTH

Rosen Law Firm is notifying Lantheus Holdings investors of a securities class action lawsuit regarding potential misleading statements about Pylarify's competitive position and pricing dynamics during February 26-August 5, 2025.

LNTH securities class action investor rights Pylarify price disclosure

Sentiment note

The lawsuit alleges the company provided false and misleading statements about Pylarify's competitive position, failed to properly disclose pricing risks, and potentially misled investors about the product's growth potential

Negative Nov 2, 2025 • 22:27 UTC GlobeNewswire Inc. • Rosen Law Firm

LNTH DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lantheus Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – LNTH

Rosen Law Firm is notifying Lantheus Holdings investors of a securities class action lawsuit regarding potential misleading statements about Pylarify's competitive position and pricing dynamics during February 26-August 5, 2025.

LNTH securities class action investor rights Pylarify price disclosure

Sentiment note

The lawsuit alleges the company provided false and misleading statements about Pylarify's competitive position, failed to properly disclose pricing risks, and potentially misled investors about the product's growth potential

Negative Oct 30, 2025 • 17:44 UTC GlobeNewswire Inc. • Glancy Prongay & Murray Llp

Deadline Alert: Lantheus Holdings, Inc. (LNTH) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Lantheus Holdings faces a class action lawsuit alleging misleading statements about its Pylarify product's market performance, with stock prices dropping significantly after missing financial estimates in Q1 and Q2 2025.

LNTH securities fraud class action Pylarify financial results stock price

Sentiment note

Stock price dropped 23.2% in May and 28.6% in August 2025 after missing financial estimates, with allegations of providing misleading information about product market dynamics and competitive positioning

Negative Oct 29, 2025 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

LNTH INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Law firm announces class action lawsuit against Lantheus Holdings for allegedly making false and misleading statements about Pylarify's competitive position and pricing dynamics during February-August 2025.

LNTH class action securities lawsuit investor alert Pylarify price increase

Sentiment note

Lawsuit alleges company concealed material adverse facts about Pylarify's competitive position, misrepresented pricing dynamics, and potentially jeopardized product's growth potential